What is the recommended treatment for orthostatic hypotension?

Treatment of Orthostatic Hypotension

Begin with non-pharmacologic interventions and medication review; if symptoms persist despite these measures, initiate midodrine as first-line pharmacologic therapy, adding fludrocortisone for inadequate response.

Initial Assessment and Reversible Causes

• Measure blood pressure after 5 minutes supine or seated, then at 1 minute and 3 minutes after standing—a drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms orthostatic hypotension. 1

• Immediately review and discontinue or switch all medications that worsen orthostatic hypotension rather than simply reducing doses—drug-induced autonomic failure is the most frequent cause. 1 The highest-risk agents include:

  • Alpha-1 blockers (doxazosin, prazosin, terazosin, tamsulosin) 1, 2
  • Centrally-acting antihypertensives (clonidine, methyldopa) 2
  • Diuretics, especially when causing volume depletion 1, 2
  • Vasodilators (hydralazine, minoxidil) 2

• Assess for volume depletion, acute blood loss, or hypovolemia as reversible contributors. 1

Non-Pharmacologic Management (Foundational for All Patients)

• Increase fluid intake to 2–3 liters daily and dietary sodium to 6–9 grams daily, unless contraindicated by heart failure or uncontrolled hypertension. 1

• Teach physical counter-pressure maneuvers—leg crossing, squatting, stooping, and muscle tensing—to be performed during symptomatic episodes, particularly effective in patients under 60 years with prodromal symptoms. 1

• Apply waist-high compression stockings (30–40 mmHg) and abdominal binders to reduce venous pooling. 1

• Elevate the head of the bed by approximately 10 degrees during sleep to prevent nocturnal polyuria, maintain favorable fluid distribution, and ameliorate nocturnal hypertension. 1

• Recommend acute water ingestion of ≥480 mL for temporary relief, with peak effect occurring 30 minutes after consumption. 1

• Advise smaller, more frequent meals to reduce post-prandial hypotension. 1

• Encourage regular physical activity and exercise to avoid deconditioning, which exacerbates orthostatic intolerance. 1

First-Line Pharmacologic Therapy

Midodrine (Strongest Evidence Base)

• Midodrine has the strongest evidence among pressor agents, supported by three randomized placebo-controlled trials demonstrating efficacy. 1, 3

• Start midodrine at 2.5–5 mg three times daily (approximately 4-hour intervals during waking hours), titrating up to 10 mg three times daily based on symptom response. 1, 3

• Administer the final dose at least 3–4 hours before bedtime (not after 6 PM) to prevent supine hypertension during sleep. 1

• Midodrine increases standing systolic blood pressure by 15–30 mmHg for 2–3 hours via peripheral α₁-adrenergic vasoconstriction. 1

• Midodrine is FDA-approved for symptomatic orthostatic hypotension, though clinical benefits (improved ability to perform life activities) require ongoing verification. 3

Second-Line or Combination Therapy

Fludrocortisone

• Add fludrocortisone 0.05–0.1 mg once daily if midodrine alone provides insufficient symptom control, titrating to 0.1–0.3 mg daily. 1, 4

• Fludrocortisone acts through sodium retention and vessel wall effects, providing a complementary mechanism to midodrine's direct vasoconstriction. 1

• Monitor for supine hypertension, hypokalemia, congestive heart failure, and peripheral edema when using fludrocortisone. 1

• Avoid fludrocortisone in patients with active heart failure, significant cardiac dysfunction, or pre-existing supine hypertension. 1

Combination Therapy for Non-Responders

• When monotherapy fails, combine midodrine with fludrocortisone—the agents act via complementary mechanisms (α₁-adrenergic vasoconstriction plus mineralocorticoid-mediated volume expansion). 1

Alternative Agents

Droxidopa

• Droxidopa is FDA-approved and particularly effective for neurogenic orthostatic hypotension in Parkinson's disease, pure autonomic failure, and multiple system atrophy. 1, 4, 5

• In Study 306B, droxidopa showed a statistically significant 0.9-unit decrease in dizziness versus placebo at Week 1 (P=0.028), though the effect did not persist beyond Week 1. 5

• The effectiveness of droxidopa beyond 2 weeks is uncertain—patients should be evaluated periodically to determine whether droxidopa continues to provide benefit. 5

• Concomitant carbidopa therapy may diminish droxidopa's effectiveness by inhibiting peripheral conversion to norepinephrine. 1

Pyridostigmine (Refractory Cases)

• Pyridostigmine (60 mg three times daily) may be added for patients refractory to midodrine and fludrocortisone, particularly when supine hypertension is a concern, as it does not worsen supine blood pressure. 1

• Pyridostigmine enhances ganglionic sympathetic transmission by inhibiting acetylcholinesterase, raising blood pressure preferentially in the upright position. 1

• Common side effects include nausea, vomiting, abdominal cramping, sweating, salivation, and urinary incontinence, which are generally manageable. 1

Special Populations

Elderly and Frail Patients

• For patients aged ≥85 years with hypertension and orthostatic hypotension, use long-acting dihydropyridine calcium channel blockers or RAS inhibitors as first-line antihypertensive agents, followed by low-dose diuretics if tolerated. 1, 2

• Defer blood pressure-lowering treatment in patients ≥85 years with moderate-to-severe frailty or limited life expectancy until blood pressure is >140/90 mmHg. 1

Diabetic Patients

• Assess for cardiovascular autonomic neuropathy in diabetic patients with orthostatic hypotension—orthostatic hypotension in diabetes often represents advanced autonomic failure. 1

• Consider α-lipoic acid for painful diabetic neuropathy, which may also benefit autonomic function. 1

Treatment Goals and Monitoring

• The therapeutic goal is minimizing postural symptoms and improving functional capacity, NOT restoring normotension. 1, 4, 6

• At each follow-up visit, measure both supine (or seated) and standing blood pressures to detect orthostatic changes and monitor for supine hypertension. 1

• Reassess patients within 1–2 weeks after medication changes to evaluate efficacy and safety. 1

• Balance the benefits of increasing standing blood pressure against the risk of worsening supine hypertension—all pressor agents can precipitate supine hypertension. 1

Common Pitfalls to Avoid

• Do not simply reduce the dose of offending medications—switch to alternative agents with minimal orthostatic impact (e.g., long-acting dihydropyridine calcium channel blockers or RAS inhibitors). 1, 2

• Do not administer midodrine after 6 PM to prevent nocturnal supine hypertension. 1

• Do not use fludrocortisone in patients with heart failure or supine hypertension. 1

• Do not combine multiple vasodilating agents (ACE inhibitors + calcium channel blockers + diuretics) without careful monitoring. 1

• Do not overlook volume depletion as a contributing factor—ensure adequate hydration before escalating pharmacologic therapy. 1